OneStream, Inc. Class A Common Stock
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Thomas Shea
- Full Time Employees
- 1,500
- Sector
- Technology
- Industry
- Software - Application
- Address
- 191 N Chester Street Birmingham DE United States of America
- IPO Date
- Jul 11, 2005
- CIK
- 0001889956
- Website
- onestream.com
- Similar Companies
- Business
- OneStream, Inc. (NASDAQ:OS) provides a unified AI-enabled enterprise finance platform that modernizes core financial functions for complex organizations worldwide; its Digital Finance Cloud offers financial close and consolidation to automate reporting and compliance tasks; financial and operational planning, budgeting, forecasting, and analysis for synchronized enterprise-wide results; reporting, analytics, and business intelligence with end-to-end visibility for executives, finance teams, and business units; account reconciliations; people, capital, and thing planning; tax provisioning; data quality management; and extensible AI-powered applications including Sensible ML and SensibleAI Agents. Founded in 2012 and headquartered in Birmingham, Michigan, the company serves over 1,600 enterprises, mid-market organizations, and government entities across more than 45 countries in North America, South America, EMEA, and APAC through a network of over 300 global partners such as Accenture, IBM, KPMG, and PwC. OneStream completed its initial public offering on July 24, 2024, at $20 per share; raised $465 million in a post-IPO secondary sale in November 2024 led by D1 Capital Partners and Tiger Global Management; acquired the remaining equity of DataSense in May 2024 for approximately $30 million to advance AI solutions; deepened its strategic partnership with Microsoft to embed SensibleAI Agents into Microsoft 365, earning Microsoft's 2025 SDC Partner of the Year for the Americas; and launched the OneStream Solution Exchange marketplace alongside AI innovations driving quadrupling Finance AI bookings.
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myel
Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progr
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
WilliamsMarston's AIT Consulting Services Wins OneStream AI Excellence Award
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMON
Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patie
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
OneStream Unveils Forward Finance Blueprint to Help CFOs Lead Enterprise AI and Future-Proof the Business
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer
These 3 Companies Crushed Key Metrics This Earnings Season